SCHEMBL4722801

SCHEMBL4722801

CCOC1OCCO[C]1c1cccc2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.40
HTR1A P08908 1/20 0.40
HTR2B P41595 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 4/20 0.36
MAPT P10636 3/20 0.36
HPGD P15428 3/20 0.36
GLA P06280 2/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
HTT P42858 1/20 0.35
PREP P48147 1/20 0.35
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765573 0.90 HTR7 (0.36) HTR7HTR1AHTR2BTMEM97SIGMAR1
SCHEMBL4765802 0.87 ALOX15 (0.37) HTR7HTR1AHTR2BTMEM97SIGMAR1
SCHEMBL4721176 0.85 MAPT (0.39) HTR7HTR1AHTR2BTMEM97SIGMAR1
SCHEMBL4721318 0.77 KDM4E (0.33) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL4724232 0.69 MAPT (0.40) HTR7HTR1AALDH1A1KDM4EMAPT
SCHEMBL4720577 0.66 MEN1 (0.33) ALDH1A1KDM4EMAPTMEN1KMT2A
Ether SCHEMBL6805648 0.65 HPGD (0.43) ALDH1A1KDM4EHPGDGAALMNA
SCHEMBL3237232 0.65 NISCH (0.46) ALDH1A1KDM4EMAPTHPGDGAA
SCHEMBL4720031 0.64 LTA4H (0.35) ALDH1A1GAALMNAL3MBTL1
Tetradecane SCHEMBL9931525 0.62 CNR1 (0.51) ALDH1A1KDM4EMAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 HTR7 136/4885HTR1A 93/4885HTR2B 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.